Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2008

View Archived Issues

Genz-29155 and sirolimus combination synergistic in renal transplant model

Studies reveal neurological effects of berberine

Effects of LY-450139 on Abeta studied with novel labeling agent 13C6-leucine

Durable safety and efficacy seen with belatacept in phase II study

Studies report efficacy of alternative regimens of enteric-coated mycophenolate in transplantation

Superior characteristics of P2Y12 inhibitor PRT-060128 detailed

Novel therapeutic agents for neurological disorders divulged in recent patents

GlaxoSmithKline reports on efforts to identify GlyT-1 inhibitors for schizophrenia

Baxter enters U.S. licensing agreement for Innocoll's gentamicin surgical implant for SSIs

FDA reports two new cases of PML in patients receiving Tysabri as monotherapy for MS

Novavax presents favorable results from phase I/IIa pandemic influenza vaccine trial

New treatment options for cancer reported in recent patent literature

CE mark for Cypher Select Plus in acute myocardial infarction

Phase IIa study of CK-1827452 successfully completes interim safety analysis

Recent Novartis patent describes new agents for respiratory disorders

Cell Genesys terminates VITAL-2 GVAX trial in advanced prostate cancer

Genmab to initiate four ofatumumab studies

M2e universal influenza vaccine candidate shows safety and immunogenicity

NexMed decides not to submit NDA for NM-100060

Pain Therapeutics and King Pharmaceuticals develop a new abuse-resistant pain medication

Photocure presents positive phase II results with Visonac for acne

Protherics commences phase IIa Prolarix study in liver cancer

Algeta presents phase II data on pain palliation with alpharadin

Arana completes enrollment in phase II ART-621 trial in psoriasis

Merck and Intercell commence phase II clinical trial of V-710 in S. aureus infection

Popular Stories

Today's news in brief
BioWorld
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
SERCA inhibitor from Sumitomo shows promise for MSA-C treatment
BioWorld Science
At the ongoing International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD 2026) in Copenhagen, Sumitomo Pharma Co....